New Lifetime High Reached By Mead Johnson Nutrition (MJN)
- MJN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $89.2 million.
- MJN has traded 14,576 shares today.
- MJN is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in MJN with the Ticky from Trade-Ideas. See the FREE profile for MJN NOW at Trade-Ideas More details on MJN: Mead Johnson Nutrition Company manufactures, distributes, and sells infant formulas, children's nutrition, and other nutritional products. The stock currently has a dividend yield of 1.6%. MJN has a PE ratio of 28.5. Currently there are 6 analysts that rate Mead Johnson Nutrition a buy, no analysts rate it a sell, and 5 rate it a hold. The average volume for Mead Johnson Nutrition has been 1.3 million shares per day over the past 30 days. Mead Johnson Nutrition has a market cap of $18.8 billion and is part of the consumer goods sector and food & beverage industry. The stock has a beta of 0.69 and a short float of 1.3% with 3.71 days to cover. Shares are up 10.5% year-to-date as of the close of trading on Friday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Mead Johnson Nutrition as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Highlights from the ratings report include:
- MJN's revenue growth has slightly outpaced the industry average of 3.1%. Since the same quarter one year prior, revenues slightly increased by 7.3%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
- MEAD JOHNSON NUTRITION CO has improved earnings per share by 8.7% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, MEAD JOHNSON NUTRITION CO increased its bottom line by earning $3.26 versus $2.96 in the prior year. This year, the market expects an improvement in earnings ($3.70 versus $3.26).
- The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and the Food Products industry average. The net income increased by 7.7% when compared to the same quarter one year prior, going from $188.00 million to $202.40 million.
- The gross profit margin for MEAD JOHNSON NUTRITION CO is rather high; currently it is at 65.53%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 18.18% is above that of the industry average.
- Investors have apparently begun to recognize positive factors similar to those we have mentioned in this report, including earnings growth. This has helped drive up the company's shares by a sharp 27.64% over the past year, a rise that has exceeded that of the S&P 500 Index. We feel that the stock's sharp appreciation over the last year has driven it to a price level which is now somewhat expensive compared to the rest of its industry. The other strengths this company shows, however, justify the higher price levels.
- You can view the full Mead Johnson Nutrition Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.